阿哌沙班与左心室功能不全患者的卒中复发风险:ARCADIA试验二次分析
该研究对ARCADIA试验中964例隐源性卒中合并心房病变患者进行事后分析,其中165例(17.1%)存在左心室收缩功能不全。调整混杂因素后,左心室收缩功能不全与卒中复发无显著关联,但阿哌沙班较阿司匹林显著降低该类患者的复发性缺血性卒中风险。
要点
- 左心室收缩功能不全患者卒中复发率数值较高,但调整后无显著关联。
- 阿哌沙班在左心室功能不全患者中显著降低卒中复发风险。
- 无左心室功能不全者中阿哌沙班与阿司匹林疗效无显著差异。
核心结论
- 在ARCADIA试验的二次分析中,阿哌沙班较阿司匹林显著降低左心室收缩功能不全患者的复发性缺血性卒中风险。
研究设计与样本
- ARCADIA试验的事后分析,纳入964例有完整超声心动图数据的隐源性卒中合并心房病变患者。
- 左心室收缩功能不全定义为左心室短轴缩短率<25%、左心室射血分数<50%或任何左心室壁运动异常。
主要发现
- 左心室收缩功能不全患者复发性缺血性卒中发生率为9.1%(15/165),无左心室收缩功能不全者为6.3%(50/799)。
- 调整不平衡协变量后,左心室收缩功能不全与复发性卒中无显著关联(风险比1.3,95%CI 0.7-2.4)。
- 左心室收缩功能不全患者中,阿哌沙班较阿司匹林显著降低复发性缺血性卒中风险(风险比0.24,95%CI 0.07-0.87)。
- 无左心室收缩功能不全患者中,阿哌沙班与阿司匹林风险无显著差异(风险比1.13,95%CI 0.65-1.96;交互作用P=0.028)。
关键数值与推荐
- 左心室收缩功能不全定义:左心室短轴缩短率<25%、左心室射血分数<50%或任何左心室壁运动异常。
- 主要结局为复发性缺血性卒中。
临床怎么用
- 对于隐源性卒中合并心房病变且存在左心室收缩功能不全的患者,阿哌沙班可能较阿司匹林更有效预防卒中复发。
局限性
- 本研究为ARCADIA试验的事后二次分析,结果需谨慎解读。
- 左心室收缩功能不全患者样本量较小(165例),事件数有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major uncertainty remains about the relationship between left ventricular (LV) systolic dysfunction, recurrent stroke, and the optimal antithrombotic therapy for secondary stroke prevention in patients with recent stroke and LV systolic dysfunction. METHODS: We performed a post hoc analysis of data from the ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a randomized trial comparing apixaban versus aspirin for secondary stroke prevention in patients with cryptogenic stroke and atrial cardiopathy. Echocardiograms were sent from 185 enrolling sites in the United States and Canada for central review at the trial echocardiography laboratory. We defined LV systolic dysfunction as LV fractional shortening <25%, LV ejection fraction <50%, or any LV wall motion abnormality. The primary outcome of interest was recurrent ischemic stroke. First, we built Cox proportional hazard models to evaluate the association between LV systolic dysfunction and recurrent ischemic stroke risk adjusted for imbalanced covariates. Next, we used Cox proportional hazard models and interaction terms to compare the effect of apixaban versus aspirin on the outcome of interest in patients with and without LV systolic dysfunction. RESULTS: Among 964 patients with complete echocardiographic data of the 1015 patients enrolled in the trial, 165 (17.1%) had LV systolic dysfunction (mean age, 67 years; 43% female; mean follow-up, 1.7 years), and 799 (82.9%) had no LV systolic dysfunction (mean age, 68 years; 56% female; mean follow-up, 1.5 years). Recurrent ischemic stroke occurred more frequently in patients with LV systolic dysfunction (n=15, 9.1%) compared with those without LV systolic dysfunction (n=50, 6.3%), but LV systolic dysfunction was not significantly associated with recurrent stroke after adjustment for imbalanced covariates (hazard ratio, 1.3 [95% CI, 0.7-2.4]). Compared with aspirin, apixaban was associated with a significantly reduced risk of recurrent ischemic stroke in patients with LV systolic dysfunction (hazard ratio, 0.24 [95% CI, 0.07-0.87]) but not in those without LV systolic dysfunction (hazard ratio, 1.13 [95% CI, 0.65-1.96]; Pinteraction=0.028). CONCLUSIONS: In a secondary analysis of the ARCADIA trial data, apixaban was associated with a significantly lower risk of recurrent ischemic stroke than aspirin in patients with LV systolic dysfunction.
引用
- Sharma R, Jillella D, Zhang C, et al. Apixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial. Stroke. 2025. PMID: 40891365. doi:10.1161/STROKEAHA.125.052724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。